NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors by Michael S. Chang, MD, Jordan T. Said, MD, Elliot H. Akama-Garren, PhD, Nicole Trepanowski, MD, Ai-Tram N. Bui, MD, Anita Giobbie-Hurder, MS, Nicole R. LeBoeuf, MD, MPH, Rebecca I. Hartman, MD, MPH

Get full text